MedyMatch Technology and IBM Watson Health have partnered to integrate MedyMatch's artificial intelligence (AI) based clinical decision support application into cognitive imaging offerings.
The move aims to assist imaging experts in hospital emergency rooms and other acute care settings, to identify instances of intracranial bleeding due to head trauma and stroke.
IBM Watson Health's Imaging group will initially distribute the MedyMatch brain bleed detection application through its vendor neutral sales channels.
The firms will then develop interoperability between MedyMatch's application and IBM Watson Health Imaging's offerings.
MedyMatch chairman and chief executive officer Gene Saragnese said: "Engaging closely with IBM allows for a near-zero footprint implementation at a customer location delivering AI to the bedside where I believe the future of healthcare lies.
"At MedyMatch, we believe improvements in the interpretation of data will lead to better decisions, better decisions will lead to better outcomes for patients and lower cost for healthcare."
The firm primarily focuses on providing cognitive tools to the emergency department for helping physicians in the assessment of presence of bleed in the brain of patients suspected of head trauma or stroke.
The MedyMatch algorithm utilises deep learning, machine vision, patient data, and clinical insights to automatically highlight the regions of interest that could indicate the potential presence of cerebral bleeds.
MedyMatch's intracranial bleed assessment application is currently undergoing a clinical trial, based on which the firm intends to apply for a pre-marketing approval (PMA) to the US Food and Drug Administration (FDA).
Image: MedyMatch's intracranial bleed detection application and 3D rendering of bleed location and volume. Photo: courtesy of IBM Watson Health.